The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis
- PMID: 19783986
- DOI: 10.1038/nsmb.1669
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis
Abstract
ID4 (inhibitor of DNA binding 4) is a member of a family of proteins that function as dominant-negative regulators of basic helix-loop-helix transcription factors. Growing evidence links ID proteins to cell proliferation, differentiation and tumorigenesis. Here we identify ID4 as a transcriptional _target of gain-of-function p53 mutants R175H, R273H and R280K. Depletion of mutant p53 protein severely impairs ID4 expression in proliferating tumor cells. The protein complex mutant p53-E2F1 assembles on specific regions of the ID4 promoter and positively controls ID4 expression. The ID4 protein binds to and stabilizes mRNAs encoding pro-angiogenic factors IL8 and GRO-alpha. This results in the increase of the angiogenic potential of cancer cells expressing mutant p53. These findings highlight the transcriptional axis mutant p53, E2F1 and ID4 as a still undefined molecular mechanism contributing to tumor neo-angiogenesis.
Similar articles
-
ID4: a new player in the cancer arena.Onco_target. 2010 May;1(1):48-58. doi: 10.18632/onco_target.108. Onco_target. 2010. PMID: 21293053 Free PMC article.
-
The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.EMBO Rep. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26. EMBO Rep. 2017. PMID: 28652379 Free PMC article.
-
Id4 dependent acetylation restores mutant-p53 transcriptional activity.Mol Cancer. 2013 Dec 13;12:161. doi: 10.1186/1476-4598-12-161. Mol Cancer. 2013. PMID: 24330748 Free PMC article.
-
Inhibitor of differentiation 4 (ID4): From development to cancer.Biochim Biophys Acta. 2015 Jan;1855(1):92-103. doi: 10.1016/j.bbcan.2014.12.002. Epub 2014 Dec 12. Biochim Biophys Acta. 2015. PMID: 25512197 Free PMC article. Review.
-
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.Endocr Relat Cancer. 2016 Sep;23(9):R381-92. doi: 10.1530/ERC-16-0196. Epub 2016 Jul 13. Endocr Relat Cancer. 2016. PMID: 27412917 Review.
Cited by
-
HIF proteins connect the RB-E2F factors to angiogenesis.Transcription. 2013 Mar-Apr;4(2):62-6. doi: 10.4161/trns.23680. Epub 2013 Feb 14. Transcription. 2013. PMID: 23412359 Free PMC article.
-
Should mutant TP53 be _targeted for cancer therapy?Cell Death Differ. 2022 May;29(5):911-920. doi: 10.1038/s41418-022-00962-9. Epub 2022 Mar 24. Cell Death Differ. 2022. PMID: 35332311 Free PMC article. Review.
-
Bioinformatics-based screening of key genes for transformation of tyrosine kinase inhibitor-resistant lung adenocarcinoma to small cell lung cancer.Front Med (Lausanne). 2023 Jul 31;10:1203461. doi: 10.3389/fmed.2023.1203461. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37583423 Free PMC article.
-
Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis.Int J Mol Sci. 2020 Feb 17;21(4):1334. doi: 10.3390/ijms21041334. Int J Mol Sci. 2020. PMID: 32079237 Free PMC article. Review.
-
CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.Breast Cancer. 2022 May;29(3):562-573. doi: 10.1007/s12282-022-01334-4. Epub 2022 Jan 30. Breast Cancer. 2022. PMID: 35094293
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous